Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs CT 1812 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms SHINE
  • Sponsors Cognition Therapeutics
  • Most Recent Events

    • 08 Nov 2018 According to a Cognition Therapeutics media release, patient dosing has been initiated in the trial.
    • 04 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 02 Oct 2018 According to a Cognition Therapeutics media release, the National Institute on Aging of the National Institute of Health has granted funds for this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top